DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

452 Barten DM, Albright CF. Therapeutic strategies for Alzheimer’s
disease. Mol Neurobiol, 2008, 37:171–186.
Bartzokis G, Lu PH, Turner J, et al. Adjunctive risperidone in
the treatment of chronic combat- related posttraumatic stress
disorder. Biol Psychiatry, 2005, 57:474–479.
Bauer M, Alda M, Priller J, Young LT, and International Group
for the Study of Lithium Treated Patients. Implications of the
neuroprotective effects of lithium for the treatment of bipolar
and neurodegenerative disorders. Pharmacopsychiatry, 2003,
36(Suppl 3):S250–S254.
Baum AE, Akula N, Cabanero M, et al. A genome-wide association
study implicates diacylglycerol kinase eta (DGKH) and
several other genes in the etiology of bipolar disorder. Mol
Psychiatry, 2008, 13:197–207.
Berman RM, Marcus RN, Swanink R, et al. The efficacy and
safety of aripiprazole as adjunctive therapy in major depressive
disorder: A multicenter, randomized, double- blind, placebocontrolled
study. J Clin Psychiatry, 2007, 68:843–853.
Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled
18-month trial of lamotrigine and lithium maintenance treatment
in recently manic or hypomanic patients with bipolar I
disorder. Arch Gen Psychiatry, 2003, 60:392–400.
Bowden CL, Swann AC, Calabrese JR, et al. A randomized,
placebo- controlled, multicenter study of divalproex sodium
extended release in the treatment of acute mania. J Clin
Psychiatry, 2006, 67:1501–1510.
Bschor T, Berghofer A, Strohle A, et al. How long should the
lithium augmentation strategy be maintained? A 1-year followup
of a placebo- controlled study in unipolar refractory major
depression. J Clin Psychopharmacol, 2002, 22:427–430.
Buchanan RW, Freedman R, Javitt DC, et al. Recent advances in
the development of novel pharmacological agents for the treatment
of cognitive impairments in schizophrenia. Schizophrenia
Bull, 2007, 33:1120–1130.
Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic,
is a high- affinity partial agonist at human dopamine
D2 receptors. J Pharmacol Exp Ther, 2002, 302:381–389.
Cade JFJ. Lithium salts in the treatment of psychotic excitement.
Med J Austral, 1949, 2:349–352.
Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled
18-month trial of lamotrigine and lithium maintenance treatment
in recently depressed patients with bipolar I disorder.
J Clin Psychiatry, 2003, 64:1013–1024.
Calabrese JR, Keck PE Jr., Macfadden W, et al. A randomized,
double- blind, placebo- controlled trial of quetiapine in the
treatment of bipolar I or II depression. Am J Psychiatry, 2005a,
162:1351–1360.
Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month,
double- blind, maintenance trial of lithium versus divalproex
in rapid- cycling bipolar disorder. Am J Psychiatry, 2005b,
162:2152–2161.
Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia.
Am J Psychiatry, 1978, 135:165–173.
Carpenter WT, Koenig JI. The evolution of drug development in
schizophrenia: past issues and future opportunities.
Neuropsychopharmacology, 2008, 33:2061–2079.
Chan WY, McKinzie DL, Bose S, et al. Allosteric modulation
of the muscarinic M4 receptor as an approach to treating
schizophrenia. Proc Natl Acad Sci USA, 2008, 105:
10978–10983.
SECTION II
NEUROPHARMACOLOGY
Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic
activity of 107 medications commonly used by older adults.
J Am Geriatr Soc, 2008, 56:1333–1341.
Chuang DM. Neuroprotective and neurotrophic actions of the
mood stabilizer lithium: Can it be used to treat neurodegenerative
diseases? Crit Rev Neurobiol, 2004, 16:83–90.
Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention
of suicidal behavior and all- cause mortality in patients
with mood disorders: A systematic review of randomized
trials. Am J Psychiatry, 2005, 162:1805–1819.
Ciranni MA, Kearney TE, Olson KR. Comparing acute toxicity of
first- and second- generation antipsychotic drugs: A 10-year, retrospective
cohort study. J Clin Psychiatry, 2009, 70:122–129.
Cooper TB, Bergner PE, Simpson GM. The 24-hour serum
lithium level as a prognosticator of dosage requirements. Am
J Psychiatry, 1973, 130:601–603.
Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic
polypharmacy increase the risk for metabolic syndrome?
Schizophr Res, 2007, 89:91–100.
Danielyan A, Kowatch RA. Management options for bipolar disorder
in children and adolescents. Paediatr Drugs, 2005, 7:
277–294.
de Leon J, Diaz FJ, Wedlund P, et al. Haloperidol half- life
after chronic dosing. J Clin Psychopharmacol, 2004, 24:
656–660.
Dixon JF, Hokin LE. Lithium acutely inhibits and chronically
up- regulates and stabilizes glutamate uptake by presynaptic
nerve endings in mouse cerebral cortex. Proc Natl Acad Sci
USA, 1998, 95:8363–8368.
Dodd S, Berk M. The safety of medications for the treatment of
bipolar disorder during pregnancy and the puerperium. Curr
Drug Saf, 2006, 1:25–33.
Einat H, Yuan P, Szabo ST, et al. Protein kinase C inhibition by
tamoxifen antagonizes manic- like behavior in rats:
Implications for the development of novel therapeutics for
bipolar disorder. Neuropsychobiology, 2007, 55:123–131.
El- Mallakh RS. Acute lithium neurotoxicity. Psychiatr Dev,
1986, 4:311–328.
Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic
treatment response in first- episode schizophrenia. Am J
Psychiatry, 2006, 163:743–745.
Expert Consensus Panel for Optimizing Pharmacologic
Treatment of Psychotic Disorders. The expert consensus
guideline series. Optimizing pharmacologic treatment of psychotic
disorders. J Clin Psychiatry, 2003, 64(Suppl 12):2–97.
Fanous AH, Kendler KS. Genetics of clinical features and subtypes
of schizophrenia: A review of the recent literature. Curr
Psychiatr Rep, 2008, 10:164–170.
Fitzgerald PB, Kapur S, Remington G, et al. Predicting haloperidol
occupancy of central dopamine D2 receptors from plasma
levels. Psychopharmacology, 2000, 149:1–5.
Flacker JM, Lipsitz LA. Serum anticholinergic activity changes
with acute illness in elderly medical patients. J Gerontol Series
A Biol Sci Med Sci, 1999, 54:M12–M16.
Freeman MP, Freeman SA. Lithium: Clinical considerations in
internal medicine. Am J Med, 2006, 119:478–481.
Glick ID, Peselow ED. New antipsychotic agents. Prim
Psychiatry, 2008, 15:57–64.
Goodnick PJ, Schorr- Cain CB. Lithium pharmacokinetics.
Psychopharmacology Bulletin, 1991, 27:475-491.